Pyrotinib
艾瑞妮(Pyrotinib)
A Chinese-developed HER2 targeted pill (Hengrui).
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved (2018, 2023); NRDL (2019)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
HER2-positive advanced breast cancer, with capecitabine.
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Pyrotinib. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.